Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 23 of 24, showing 10 Applications out of 238 total, starting on record 221, ending on 230

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

221.

ECCT/25/08/02   MK-8527-010
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women.   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
1. KEMRI CMR RCTP (Kisumu county)
 
21-11-2025 View

222.

ECCT/25/08/04   MK-8527-010 PrEP
    A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Oral MK-8527 Once-Monthly as HIV-1 Preexposure Prophylaxis in Cisgender Women    
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
1. KEMRI-CCR PHRD Thika (Kiambu county)
 
25-11-2025 View

223.

ECCT/25/08/05   Floral roll over study
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study.   
Principal Investigator(s)
1. Dr. Isaac Tsikhutsu
Site(s) in Kenya
1. KEMRI WALTER REED KERICHO (Kericho county)
2. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Gertrudes Childrens Hospital (Nairobi City county)
5. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
6. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
7. KEMRI Kondele Children\'s Hospital (Kisumu county)
 
09-02-2026 View

224.

ECCT/25/08/06   MK-8527-010
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women   
Principal Investigator(s)
1. Irene Wambui Inwani
Site(s) in Kenya
1. UW-KNH; Rachuonyo County Hospital, Oyugis (Homa Bay county)
2. KEMRI-CMR-RCTP KEMRI CIS Building (Kisumu county)
3. Kargeno Research & Policy Hub (Kisumu county)
4. KEMRI-CCR-PHRD, Thika site (Kiambu county)
 
15-12-2025 View

225.

ECCT/25/08/08   PROPS Trial
    Efficacy of probiotic supplementation in preterm and small for gestational age infants. A multi-centre, placebo-controlled, individually-randomised trial   (Probiotics in preterm and small for gestational age infants, PROPS trial)   
Principal Investigator(s)
1. Maureen Muchela
Site(s) in Kenya
1. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
2. Homabay County Referral Hospital (Homa Bay county)
3. Kisii Teaching and Referral Hospital (Kisii county)
4. Migori County Referral Hospital (Migori county)
 
29-04-2026 View

226.

ECCT/25/09/01   VLA1553-404
    VLA1553-404: A Pragmatic Randomised Controlled Trial to Evaluate the Effectiveness and Safety of VLA1553 against Chikungunya Virus Disease   
Principal Investigator(s)
1. Prof. Videlis Nduba
Site(s) in Kenya
1. KEMRI-MTWAPA (Kilifi county)
 
21-01-2026 View

227.

ECCT/25/11/01   COMBO-CONSTELLATION
    A Phase 3, randomized, double-blind, placebo-controlled trial to evaluate the effect of Bifidobacterium longum subsp. infantis DSM33361(Bifin02) administered together with Lacticaseibacillus rhamnosus GG DSM33156 (LGG®) versus placebo on weight gain in underweight infants   
Principal Investigator(s)
1. Dr. Wilson Muraya
Site(s) in Kenya
1. KENYA MEDICAL RESEARCH INSTITUTE- MTWAPA (Kilifi county)
2. Moi University Clinical Research Centre-MUCRU (Uasin Gishu county)
3. Kenya Medical Research Institute (KEMRI) CRDR (Nairobi City county)
 
21-06-2026 View

228.

ECCT/25/11/03   RSV IMPACT TRIAL
    A Phase-IIIb individually randomized, placebo-controlled trial on safety of RSVA/B-preF vaccine in pregnant women and efficacy against severe RSV-associated lower respiratory tract infection in infants.   
Principal Investigator(s)
1. Nancy A. Otieno
2. Evans M. Ogoti
Site(s) in Kenya
Kenya Medical Research Institute, Centre for Global Health Research - Siaya (KE1)
 
09-02-2026 View

229.

ECCT/25/11/04   Bifin02 and LGG®
    A Phase 3, randomized, double-blind, placebo-controlled trial to evaluate the effect of Bifidobacterium longum subsp. infantis DSM33361(Bifin02) administered together with Lacticaseibacillus rhamnosus GG DSM33156 (LGG®) versus placebo on weight gain in underweight infants   
Principal Investigator(s)
1. Charity Wambui Kanyoro
Site(s) in Kenya
1. Moi University Clinical Research (Uasin Gishu county)
2. Kenya Medical Research Institute (KEMRI) CRDR Off Raila Odinga, Nairobi Kenya (Nairobi City county)
3. Kenya Medical Research Institute (KEMRI) Mwtapa (Kilifi county)
 
19-08-2026 View

230.

ECCT/25/11/05   MK-8527-011 Study
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis   
Principal Investigator(s)
1. Dr. Joshua Kimani
Site(s) in Kenya
1. Nyanza Reproductive Health Society (NRHS), UNIM Research and Training Centre (URTC) (Kisumu county)
2. Partners for Health and Development in Africa – Sex workers Outreach Program (PHDA – SWOP) Clinic- Nairobi, Kenya (Nairobi City county)
3. Kenya Impact Research and Development Organization (K-IRDO) (Kisumu county)
 
05-03-2026 View